Cargando…
An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks
Major depressive disorder (MDD) is a leading cause of global disability with a chronic and recurrent course. Recognition of biological markers that could predict and monitor response to drug treatment could personalize clinical decision-making, minimize unnecessary drug exposure, and achieve better...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692261/ https://www.ncbi.nlm.nih.gov/pubmed/33126421 http://dx.doi.org/10.3390/biomedicines8110455 |
_version_ | 1783614469423759360 |
---|---|
author | Kim, Eun Young Ahn, Hee-Sung Lee, Min Young Yu, Jiyoung Yeom, Jeonghun Jeong, Hwangkyo Min, Hophil Lee, Hyun Jeong Kim, Kyunggon Ahn, Yong Min |
author_facet | Kim, Eun Young Ahn, Hee-Sung Lee, Min Young Yu, Jiyoung Yeom, Jeonghun Jeong, Hwangkyo Min, Hophil Lee, Hyun Jeong Kim, Kyunggon Ahn, Yong Min |
author_sort | Kim, Eun Young |
collection | PubMed |
description | Major depressive disorder (MDD) is a leading cause of global disability with a chronic and recurrent course. Recognition of biological markers that could predict and monitor response to drug treatment could personalize clinical decision-making, minimize unnecessary drug exposure, and achieve better outcomes. Four longitudinal plasma samples were collected from each of ten patients with MDD treated with antidepressants for 10 weeks. Plasma proteins were analyzed qualitatively and quantitatively with a nanoflow LC−MS/MS technique. Of 1153 proteins identified in the 40 longitudinal plasma samples, 37 proteins were significantly associated with response/time and clustered into six according to time and response by the linear mixed model. Among them, three early-drug response markers (PHOX2B, SH3BGRL3, and YWHAE) detectable within one week were verified by liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) in the well-controlled 24 patients. In addition, 11 proteins correlated significantly with two or more psychiatric measurement indices. This pilot study might be useful in finding protein marker candidates that can monitor response to antidepressant treatment during follow-up visits within 10 weeks after the baseline visit. |
format | Online Article Text |
id | pubmed-7692261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76922612020-11-28 An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks Kim, Eun Young Ahn, Hee-Sung Lee, Min Young Yu, Jiyoung Yeom, Jeonghun Jeong, Hwangkyo Min, Hophil Lee, Hyun Jeong Kim, Kyunggon Ahn, Yong Min Biomedicines Article Major depressive disorder (MDD) is a leading cause of global disability with a chronic and recurrent course. Recognition of biological markers that could predict and monitor response to drug treatment could personalize clinical decision-making, minimize unnecessary drug exposure, and achieve better outcomes. Four longitudinal plasma samples were collected from each of ten patients with MDD treated with antidepressants for 10 weeks. Plasma proteins were analyzed qualitatively and quantitatively with a nanoflow LC−MS/MS technique. Of 1153 proteins identified in the 40 longitudinal plasma samples, 37 proteins were significantly associated with response/time and clustered into six according to time and response by the linear mixed model. Among them, three early-drug response markers (PHOX2B, SH3BGRL3, and YWHAE) detectable within one week were verified by liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) in the well-controlled 24 patients. In addition, 11 proteins correlated significantly with two or more psychiatric measurement indices. This pilot study might be useful in finding protein marker candidates that can monitor response to antidepressant treatment during follow-up visits within 10 weeks after the baseline visit. MDPI 2020-10-28 /pmc/articles/PMC7692261/ /pubmed/33126421 http://dx.doi.org/10.3390/biomedicines8110455 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Eun Young Ahn, Hee-Sung Lee, Min Young Yu, Jiyoung Yeom, Jeonghun Jeong, Hwangkyo Min, Hophil Lee, Hyun Jeong Kim, Kyunggon Ahn, Yong Min An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
title | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
title_full | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
title_fullStr | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
title_full_unstemmed | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
title_short | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
title_sort | exploratory pilot study with plasma protein signatures associated with response of patients with depression to antidepressant treatment for 10 weeks |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692261/ https://www.ncbi.nlm.nih.gov/pubmed/33126421 http://dx.doi.org/10.3390/biomedicines8110455 |
work_keys_str_mv | AT kimeunyoung anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT ahnheesung anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT leeminyoung anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT yujiyoung anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT yeomjeonghun anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT jeonghwangkyo anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT minhophil anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT leehyunjeong anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT kimkyunggon anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT ahnyongmin anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT kimeunyoung exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT ahnheesung exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT leeminyoung exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT yujiyoung exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT yeomjeonghun exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT jeonghwangkyo exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT minhophil exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT leehyunjeong exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT kimkyunggon exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT ahnyongmin exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks |